サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1434971

アルツハイマー治療薬市場：薬剤クラス別、タイプ別、流通別-2024-2030年の世界予測

Alzheimer's Therapeutics Market by Drug Class (Cholinesterase Inhibitors, NMDA [N-methyl-D-aspartate] Receptor Antagonist), Type (Medication, NMDA Receptor Antagonist), Distribution - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 196 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
アルツハイマー治療薬市場：薬剤クラス別、タイプ別、流通別-2024-2030年の世界予測
出版日: 2024年01月16日
発行: 360iResearch
ページ情報: 英文 196 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

アルツハイマー治療薬市場規模は2023年に61億4,000万米ドルと推計され、2024年には66億6,000万米ドルに達し、CAGR 8.63%で2030年には109億6,000万米ドルに達すると予測されます。

アルツハイマー治療薬の世界市場

主な市場の統計
基準年[2023］ 61億4,000万米ドル
予測年[2024］ 66億6,000万米ドル
予測年 [2030] 109億6,000万米ドル
CAGR（%） 8.63%
アルツハイマー治療薬 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスはアルツハイマー治療薬市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、アルツハイマー治療薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-アルツハイマー治療薬市場の市場規模および予測は？

2-アルツハイマー治療薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-アルツハイマー治療薬市場における技術動向と規制の枠組みは？

4-アルツハイマー治療薬市場における主要ベンダーの市場シェアは？

5-アルツハイマー治療薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 人口におけるアルツハイマー病の発生率の増加
      • パイプライン医薬品の開発と利用可能性の拡大
      • アルツハイマー病の早期発見のためのヘルスケア施設と技術の改善
    • 抑制要因
      • 資本集約的なアルツハイマー病治療
    • 機会
      • クラウドベースの認知システムと人工知能を含む集中的な研究開発
      • 新規バイオマーカーと新たな再生療法の開発
    • 課題
      • 厳格な医薬品承認プロセス
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 アルツハイマー治療薬市場薬剤クラス別

  • コリンエステラーゼ阻害剤
  • NMDA[N-メチル-D-アスパラギン酸]受容体拮抗薬

第7章 アルツハイマー治療薬市場：タイプ別

  • 薬
    • コリンエステラーゼ阻害剤
    • ドネペジル
    • ガランタミン
    • リバスチグミン
  • NMDA受容体拮抗薬

第8章 アルツハイマー治療薬市場配信別

  • オンライン薬局
  • 小売薬局

第9章 南北アメリカのアルツハイマー治療薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域のアルツハイマー治療薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカのアルツハイマー治療薬市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析
    • 新製品発売と機能強化

第13章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • AbbVie Inc.
    • AC Immune SA
    • Acadia Pharmaceuticals Inc.
    • Alnylam Pharmaceuticals, Inc.
    • AlzeCure Pharma AB
    • Alzheon, Inc.
    • AstraZeneca PLC
    • Biogen Inc.
    • Cassava Sciences, Inc.
    • Cognition Therapeutics, Inc.
    • Corium, Inc.
    • Eisai Co., Ltd.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • Grifols S.A.
    • H. Lundbeck A/S
    • Luye Pharma Group Ltd.
    • Merz Pharma GmbH & Co. KGaA
    • NeuroVision Imaging, Inc.
    • Novartis AG
    • Oryzon Genomics, S.A.
    • Pfizer, Inc.
    • Siemens Healthcare GmbH
    • Synaptogenix, Inc.
    • TauRx Pharmaceuticals Ltd.
    • VTV Therapeutics
  • 主要な製品ポートフォリオ

第14章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. ALZHEIMER'S THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. ALZHEIMER'S THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. ALZHEIMER'S THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ALZHEIMER'S THERAPEUTICS MARKET DYNAMICS
  • FIGURE 7. ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 8. ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 10. ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 12. ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ALZHEIMER'S THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. ALZHEIMER'S THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. ALZHEIMER'S THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. ALZHEIMER'S THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 6. ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY NMDA [N-METHYL-D-ASPARTATE] RECEPTOR ANTAGONIST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 9. ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 11. ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DONEPEZIL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GALANTAMINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY RIVASTIGMINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY NMDA RECEPTOR ANTAGONIST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 17. ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 50. AUSTRALIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 54. CHINA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 58. INDIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. INDIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 62. INDONESIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. INDONESIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 66. JAPAN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. JAPAN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 70. MALAYSIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. MALAYSIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 74. PHILIPPINES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. PHILIPPINES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 78. SINGAPORE ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. SINGAPORE ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 82. SOUTH KOREA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH KOREA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 86. TAIWAN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. TAIWAN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 90. THAILAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. THAILAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 94. VIETNAM ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. VIETNAM ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 103. DENMARK ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 104. DENMARK ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 107. EGYPT ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 108. EGYPT ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 111. FINLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. FINLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 115. FRANCE ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. FRANCE ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 119. GERMANY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. GERMANY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 123. ISRAEL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. ISRAEL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 127. ITALY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. ITALY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 131. NETHERLANDS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 132. NETHERLANDS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 135. NIGERIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. NIGERIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 139. NORWAY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 140. NORWAY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 143. POLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. POLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 147. QATAR ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. QATAR ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 151. RUSSIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 152. RUSSIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 155. SAUDI ARABIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 156. SAUDI ARABIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 159. SOUTH AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 163. SPAIN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 164. SPAIN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 167. SWEDEN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 168. SWEDEN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 171. SWITZERLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 172. SWITZERLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 175. TURKEY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 176. TURKEY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 179. UNITED ARAB EMIRATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 180. UNITED ARAB EMIRATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED KINGDOM ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED KINGDOM ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 187. ALZHEIMER'S THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 188. ALZHEIMER'S THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 189. ALZHEIMER'S THERAPEUTICS MARKET LICENSE & PRICING
目次
Product Code: MRR-A77F2EE7AAEF

[196 Pages Report] The Alzheimer's Therapeutics Market size was estimated at USD 6.14 billion in 2023 and expected to reach USD 6.66 billion in 2024, at a CAGR 8.63% to reach USD 10.96 billion by 2030.

Global Alzheimer's Therapeutics Market

KEY MARKET STATISTICS
Base Year [2023] USD 6.14 billion
Estimated Year [2024] USD 6.66 billion
Forecast Year [2030] USD 10.96 billion
CAGR (%) 8.63%
Alzheimer's Therapeutics Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Alzheimer's Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Alzheimer's Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Alzheimer's Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AC Immune SA, Acadia Pharmaceuticals Inc., Alnylam Pharmaceuticals, Inc., AlzeCure Pharma AB, Alzheon, Inc., AstraZeneca PLC, Biogen Inc., Cassava Sciences, Inc., Cognition Therapeutics, Inc., Corium, Inc., Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Grifols S.A., H. Lundbeck A/S, Luye Pharma Group Ltd., Merz Pharma GmbH & Co. KGaA, NeuroVision Imaging, Inc., Novartis AG, Oryzon Genomics, S.A., Pfizer, Inc., Siemens Healthcare GmbH, Synaptogenix, Inc., TauRx Pharmaceuticals Ltd., and VTV Therapeutics.

Market Segmentation & Coverage

This research report categorizes the Alzheimer's Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Class
    • Cholinesterase Inhibitors
    • NMDA [N-methyl-D-aspartate] Receptor Antagonist
  • Type
    • Medication
      • Cholinesterase inhibitors
      • Donepezil
      • Galantamine
      • Rivastigmine
    • NMDA Receptor Antagonist
  • Distribution
    • Online Pharmacies
    • Retail Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Alzheimer's Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Alzheimer's Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Alzheimer's Therapeutics Market?

4. What is the market share of the leading vendors in the Alzheimer's Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Alzheimer's Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Alzheimer's Therapeutics Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of Alzheimer's among population
      • 5.1.1.2. Growing development and availability of pipeline drugs
      • 5.1.1.3. Improved healthcare facilities and technologies for early detection of Alzheimer's
    • 5.1.2. Restraints
      • 5.1.2.1. Capital intensive treatment for Alzheimer's
    • 5.1.3. Opportunities
      • 5.1.3.1. Intense research and development with inclusion of cloud-based cognitive systems and artificial intelligence
      • 5.1.3.2. Development of novel biomarkers and emerging regenerative therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent drug approval processes
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Alzheimer's Therapeutics Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Cholinesterase Inhibitors
  • 6.3. NMDA [N-methyl-D-aspartate] Receptor Antagonist

7. Alzheimer's Therapeutics Market, by Type

  • 7.1. Introduction
  • 7.2. Medication
    • 7.3.1. Cholinesterase inhibitors
    • 7.3.2. Donepezil
    • 7.3.3. Galantamine
    • 7.3.4. Rivastigmine
  • 7.3. NMDA Receptor Antagonist

8. Alzheimer's Therapeutics Market, by Distribution

  • 8.1. Introduction
  • 8.2. Online Pharmacies
  • 8.3. Retail Pharmacies

9. Americas Alzheimer's Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Alzheimer's Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Alzheimer's Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player
    • 12.3.1. New Product Launch & Enhancement
      • 12.3.1.1. The Next Phase of Alzheimer's Therapeutics with Alzstatin ACD680
      • 12.3.1.2. Alzecure Selects CD and Enters Next Development Phase with Alzstatin ACD680 against Alzheimer's

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. AbbVie Inc.
    • 13.1.2. AC Immune SA
    • 13.1.3. Acadia Pharmaceuticals Inc.
    • 13.1.4. Alnylam Pharmaceuticals, Inc.
    • 13.1.5. AlzeCure Pharma AB
    • 13.1.6. Alzheon, Inc.
    • 13.1.7. AstraZeneca PLC
    • 13.1.8. Biogen Inc.
    • 13.1.9. Cassava Sciences, Inc.
    • 13.1.10. Cognition Therapeutics, Inc.
    • 13.1.11. Corium, Inc.
    • 13.1.12. Eisai Co., Ltd.
    • 13.1.13. Eli Lilly and Company
    • 13.1.14. F. Hoffmann-La Roche Ltd.
    • 13.1.15. Grifols S.A.
    • 13.1.16. H. Lundbeck A/S
    • 13.1.17. Luye Pharma Group Ltd.
    • 13.1.18. Merz Pharma GmbH & Co. KGaA
    • 13.1.19. NeuroVision Imaging, Inc.
    • 13.1.20. Novartis AG
    • 13.1.21. Oryzon Genomics, S.A.
    • 13.1.22. Pfizer, Inc.
    • 13.1.23. Siemens Healthcare GmbH
    • 13.1.24. Synaptogenix, Inc.
    • 13.1.25. TauRx Pharmaceuticals Ltd.
    • 13.1.26. VTV Therapeutics
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing